Document Detail


Has umbilical cord blood transplantation for AML become mainstream?
MedLine Citation:
PMID:  23314845     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE OF REVIEW: We discuss outcomes after umbilical cord blood (UCB) transplantation (UCBT) for patients with acute myeloid leukemia (AML) and compare these outcomes to results after transplantation of other allogeneic graft sources.
RECENT FINDINGS: Survival after UCBT has improved considerably over the past 10 years. Multiple retrospective studies using either myeloablative or reduced intensity conditioning have shown disease-free survival after UCBT that is comparable to that of matched related or unrelated donors. Improved unit selection, conditioning, graft manipulation, and supportive care are all emerging strategies to further improve outcomes, although disease status and center expertise remain key components of successful UCBT outcome.
SUMMARY: UCBT should be considered in all high-risk AML patients in whom allogeneic stem cell transplantation is indicated but who lack a matched related or unrelated donor. UCBT can thereby now be thought of as a 'mainstream' treatment of high-risk AML.
Authors:
Karen K Ballen; Juliet N Barker
Related Documents :
23777935 - Role of anti-vimentin antibodies in allograft rejection.
3937885 - Partitioning of regulatory sites in bufo marinus during hypercapnia.
24443785 - Post- liver transplantation sarcopenia in cirrhosis: a prospective evaluation.
24752065 - Chronic mucosal inflammation/inflammatory bowel disease-like inflammation after intesti...
19812495 - Immunosuppression in high-risk transplantation.
23262045 - Immunosuppression with tacrolimus early after orthotopic heart transplantation: a compa...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current opinion in hematology     Volume:  20     ISSN:  1531-7048     ISO Abbreviation:  Curr. Opin. Hematol.     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-05     Completed Date:  2013-07-09     Revised Date:  2014-01-30    
Medline Journal Info:
Nlm Unique ID:  9430802     Medline TA:  Curr Opin Hematol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  144-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cord Blood Stem Cell Transplantation* / methods
Humans
Leukemia, Myeloid, Acute / therapy*
Survival Analysis
Grant Support
ID/Acronym/Agency:
P01 CA023766/CA/NCI NIH HHS

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hematopoietic stem cell transplantation for myelofibrosis: where are we now?
Next Document:  ER stress signalling through eIF2? and CHOP, but not IRE1?, attenuates adipogenesis in mice.